newsfilter
← Interviews
Baron Capital14 min

Attractive SMID Cap Stocks Amid Tech Turbulence

Randy Gwirtzman, Caroline

Interview
  • Market Rotation Drivers

    • Small and mid-cap (SMID) stocks are currently under-allocated, representing only 3% of the Russell 3000 versus a historical norm of 7.5%.
    • Valuation metrics suggest upside potential, with the Russell 2500 Growth index trading at 21.5x forward earnings, roughly half a multiple below the S&P 500 and within its typical 20–22x range.
    • Growth differentiation is evident in sales projections: the Barron SMID ETF (BCSM) is projected to grow at 20%, compared to 16% for the S&P 500 and 11% for next year's sales.
    • The macroeconomic environment supports this shift through inflation trending below 3% and potential GDP growth forecasts reaching 5%.
  • Sector-Specific Shifts and AI Dynamics

    • Capital expenditure for AI data centers is surging from $200 billion in 2024 to an expected $400 billion in 2025 and $650 billion subsequently.
    • Hardware and semiconductor providers (e.g., Coherent) are benefiting directly from this build-out, while software companies face valuation compression.
    • Software valuations have tightened significantly, with small-cap software down 40% year-to-date and some lower-growth entities trading at 3.5x forward sales, below 2015 levels.
    • Specific software stocks like Datadog and Dynatrace are identified as resilient despite sector-wide pressure due to their embedded network infrastructure roles.
      • Dynatrace trades at 13x free cash flow while growing FCF in the high teens.
    • Risk exists for seat-based business models in code generation and legal software where AI can displace human labor tasks.
  • Key Holdings and Thematic Investments

    • Axon: Selected for its hybrid "atoms and electrons" model, leveraging physical sensors (body cams, tasers) to feed proprietary AI data that cannot be replicated by software-only agentic models.
    • Tempus AI: Positioned at the intersection of healthcare and AI, utilizing a proprietary database of genetic and outcomes-based data to aid drug development and cancer diagnostics.
    • Biologics Supply Chain: Investments include Repligen (biologic manufacturing equipment) and Stevanato (glass tubing for auto-injectors used in GLP-1 and PCSK-9 therapies).
  • Investment Strategy and Forward Outlook

    • Barron Capital employs a three-to-five-year horizon focused on identifying companies capable of doubling or tripling free cash flow.
    • The firm emphasizes deep fundamental research, including management interviews and competitor analysis, to navigate the volatility of small-cap markets.
    • A broader market is viewed as economically healthier, reducing reliance on mega-cap concentration and potentially benefiting consumer sectors via tax rebates.
    • The strategy expects the current valuation disconnect between small/mid-caps and large-caps to normalize as the rate cycle transitions toward lower rates.